仁度生物上半年营收8124万元，研发、国际化筑中长期增长根基

Core Viewpoint - RenDu Bio (688193) reported a decline in revenue and net profit for the first half of 2025, but is positioning itself for long-term growth through technological innovation and international expansion [1][2][3] Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% compared to the previous year [1] Product Development and Innovation - RenDu Bio focused on building new technology platforms and developing new product lines, successfully creating the "Digital SAT + Automatic Supporting Equipment DigiNAT" platform - This platform offers significant advantages over traditional digital PCR technology, including reduced DNA background interference and improved detection speed - The company is developing RNA digital quantitative detection products, particularly for cancer screening and diagnosis, with progress in prostate and bladder cancer tests [2] Market Opportunities - The global liquid biopsy market is expected to maintain a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments - The rising demand for early screening and diagnosis of high-incidence tumors like prostate and bladder cancer presents a significant opportunity for the company [2] International Expansion - RenDu Bio has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India - The company has also secured IVDR CE certification for its Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents, enhancing its ability to enter the EU market [3] Regulatory and Competitive Landscape - The IVDR certification signifies the company's strong capabilities in product development and compliance, which is crucial in the highly regulated EU market - The successful certification of key products highlights the company's systematic advantages in research, clinical translation, and regulatory compliance, laying a solid foundation for future international registrations [3]